Dr Guy Pratt is a consultant haematologist with a long-standing research interest in multiple myeloma and chronic lymphocytic leukaemia.
Consultant Haematologist, University Hospitals Birmingham NHS Foundation Trust, Birmingham
Honorary Senior Lecturer at the Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham
Background and Research focus
Dr Guy Pratt is a Consultant Haematologist who initially worked as a clinical academic in the School of Cancer Sciences in the University of Birmingham/Heart of England NHS Trust and more recently at University Hospitals Birmingham NHS Foundation Trust. His main research interests are multiple myeloma and chronic lymphocytic leukaemia (CLL) and he is actively involved in supporting basic research, in developing guidelines, in clinical trials in these diseases and sits as secretary on the executive board of the UK Myeloma Forum. He is scientific secretary for the British Society of Haematology (BSH) (2017-). He has a longstanding interest in guidelines and was clinical lead for the NICE Myeloma guideline 2016 and is currently chair for Haemato-Oncology guidelines for BSH (2017-). Multiple myeloma is the second most common haematological cancer characterized by neoplastic plasma cells accumulating in the bone marrow. Dr Pratt has a long-standing research interest in characterizing the T cell disturbance and examining differences in the tumour cell microenvironment in blood and bone marrow in patients afflicted with plasma cell disorders. Dr Pratt has also fostered a plethora of collaborations both with national and industry based groups focused on research and developing clinical drugs and has a mounting publication output (130+ peer reviewed publications).
Haematology; Haemato-Oncology; multiple myeloma; chronic lymphocytic leukaemia; tumour immunotherapy; tumour immunology; T-cell immunity.
Dr Pratt has a particular interest in Haemato-Oncology. He serves as an honorary Senior Lecturer at the Institute of Immunology and Immunotherapy. He also makes substantial contributions in mentoring and teaching medical students and BMed Sci students, co-supervising PhD students and mentoring junior doctors. He regularly peer reviews for a number of journals, grant holders and frequently serves as an external examiner. He regularly lectures to patients and relatives on Myeloma and Waldenstroms UK Info days organised by the patient support groups, Myeloma UK and Waldenstroms UK, as well as serving as a Trustee for the British Society of Haematology (2015-2018), Cure Leukaemia and Waldenstroms UK.
Chantry A, Kazmi M, Barrington S, Goh V, Mulholland N, Streetly M, Lai M, Pratt G; British Society for Haematology Guidelines. Guidelines for the use of imaging in the management of patients with myeloma. Br J Haematol. 2017 Aug;178(3):380-393. doi: 10.1111/bjh.14827. Epub 2017 Jul 5.
Pratt G, Yap C, Oldreive C, Slade D, Bishop R, Griffiths M, Dyer MJS, Fegan C, Oscier D, Pettitt A, Matutes E, Devereux S, Allsup D, Bloor A, Hillmen P, Follows G, Rule S, Moss P, Stankovic T. A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. Br J Haematol. 2017 Jun 23. doi: 10.1111/bjh.14793. [Epub ahead of print]
Goodyear OC, Essex S, Seetharam A, Basu S, Moss P, Pratt G. Neoplastic plasma cells generate an inflammatory environment within bone marrow and markedly alter the distribution of T cells between lymphoid compartments. Oncotarget. 2017 May 2;8(18):30383-30394. doi: 10.18632/oncotarget.16628.
Snowden JA, Greenfield DM, Bird JM, Boland E, Bowcock S, Fisher A, Low E, Morris M, Yong K, Pratt G; UK Myeloma Forum (UKMF) and the British Society for Haematology (BSH). Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. Br J Haematol. 2017Mar;176(6):888-907. doi: 10.1111/bjh.14514. Epub 2017 Jan 20.
Pratt G. Panobinostat plus bortezomib and dexamethasone for relapsed myeloma. Lancet Haematol. 2016 Nov;3(11):e498-e499. doi: 10.1016/S2352-3026(16)30133-8. Epub 2016 Oct 14.
Parry HM, Stevens T, Oldreive C, Zadran B, McSkeane T, Rudzki Z, Paneesha S, Chadwick C, Stankovic T, Pratt G, Zuo J, Moss P. NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma. Oncotarget. 2016 Oct18;7(42):68513-68526. doi: 10.18632/oncotarget.12097.
Pratt G. A selective histone deacetylase inhibitor for myeloma. Lancet Oncol. 2016 Nov;17(11):1472-1474. doi: 10.1016/S1470-2045(16)30407-7. Epub 2016 Sep 17.
McNee G, Eales KL, Wei W, Williams DS, Barkhuizen A, Bartlett DB, Essex S, Anandram S, Filer A, Moss PA, Pratt G, Basu S, Davies CC, Tennant DA. Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma. Leukemia. 2017 Feb;31(2):373-381. doi: 10.1038/leu.2016.187. Epub 2016 Jul 11.
Pratt G, Thomas P, Marden N, Alexander D, Davis Z, Hussey D, Parry H, Harding S, Catovsky D, Begley J, Oscier D. Evaluation of serum markers in the LRF CLL4 trial: β2-microglobulin but not serum free light chains, is an independent marker of overall survival. Leuk Lymphoma. 2016 Oct;57(10):2342-50. doi:10.3109/10428194.2015.1137291. Epub 2016 Feb 8.
Ludwig C, Williams DS, Bartlett DB, Essex SJ, McNee G, Allwood JW, Jewell E, Barkhuisen A, Parry H, Anandram S, Nicolson P, Gardener C, Seymour F, Basu S, Dunn WB, Moss PA, Pratt G, Tennant DA. Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma. Blood Cancer J. 2015 Oct 16;5:e359. doi: 10.1038/bcj.2015.85.